Username:
Password:
Forgot password?
07 April 2016
The recent publication of the Panama papers, combined with the US government calling off the USD 160bn Pfizer/Allegan deal amid tax inversion rule changes, mean dealmakers look likely to face a number of small term challenges.
Posted by Lisa Wright at 14:18PM
Zephyr director Lisa Wright shares her analysis and opinion on news and trends in M&A, private equity, venture capital and IPOs. Lisa’s insight and experience comes from 15 years of working with products that track deal activity.
Follow me by clicking the RSS icon above.